NBTX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Nanobiotix S.A. (NBTX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C- (2.1) | C+ (2.7) | B (3.3) | D+ (1.6) | C+ (2.6) | C (2.5) |
| 2026-11-06 | C (2.2) | C+ (2.7) | B (3.3) | C- (1.9) | C+ (2.7) | C+ (2.5) |
| 2026-10-30 | C- (2.1) | C+ (2.6) | B (3.3) | C+ (2.6) | C+ (2.7) | C+ (2.6) |
| 2026-10-23 | C (2.2) | C+ (2.6) | B (3.2) | C+ (2.5) | C+ (2.6) | C+ (2.6) |
| 2026-10-16 | C (2.4) | C+ (2.6) | B (3.2) | C (2.2) | C+ (2.6) | C+ (2.6) |